GSK plc (BVMF:G1SK34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 525.34B +22.1% |
| Revenue (ttm) | 225.81B +4.0% |
| Net Income | 40.15B +84.9% |
| EPS | 9.78 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.08 |
| Forward PE | 10.26 |
| Dividend | 1.66 (3.13%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 240 |
| Open | 53.95 |
| Previous Close | 53.95 |
| Day's Range | 52.75 - 53.95 |
| 52-Week Range | 39.98 - 63.24 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK announces EMA accepted submission to update Bexsero label
GSK (GSK) announced the European Medicines Agency, EMA, has accepted a submission to update the label for Bexsero to include a single dose booster for individuals aged 10 years and…
Trevi Therapeutics price target raised to $40 from $29 at Clear Street
Clear Street raised the firm’s price target on Trevi Therapeutics (TRVI) to $40 from $29 and keeps a Buy rating on the shares after GSK (GSK) discontinued camlipixant in refractory…
GSK: EMA Accepts Filing For Bexsero Single-Dose Booster In Adolescents
(RTTNews) - GSK plc (GSK) announced that the European Medicines Agency (EMA) has accepted its submission to update the label for Bexsero, aiming to include a single-dose booster for individuals aged 1...
GSK Drops Chronic Cough Drug as Shares Fall 4.5%
GSK Drops Chronic Cough Drug as Shares Fall 4.5%
GSK Shares Decline After Camlipixant Trial Setback
GSK Shares Decline After Camlipixant Trial Setback
GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
GSK shares fell after the U.K. drugmaker said it would stop working on an experimental treatment for chronic cough after mixed results showed limited efficacy in late-stage clinical studies.
GSK Ceases Phase 3 Development Of Camlipixant In Chronic Cough, Advances Drug For IBS
(RTTNews) - GSK plc (GSK), a biopharmaceutical company, on Friday announced the discontinuation of Phase 3 development for Camlipixant in treating refractory chronic cough (RCC).
GSK: Clinical Trials Update on Camlipixant for Chronic Cough
GSK: Clinical Trials Update on Camlipixant for Chronic Cough
GSK Stock Weakens After Failed Drug Trial to Help Patients Coughing 900 Times a Day
Shares in drugs giant GlaxoSmithKline ($GSK) were off-color today after it revealed that it was halting development of a chronic cough treatment after failed trials. The group said that experimental…
GSK will not pursue further development of camlipixant in RCC
GSK (GSK) provided an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant in adults with refractory chronic…
GSK Decides Not To Progress Development Of Camlipixant In Refractory Chronic Cough
(RTTNews) - GSK plc (GSK, GSK.L) issued an update on the CALM-1 and CALM-2 phase III clinical trials, which assessed the efficacy and safety of two doses of camlipixant in adults with refractory chron...
GSK to halt further development of cough drug after missing main goal
GSK on Friday said it had decided not to develop its experimental drug to treat refractory chronic cough further after it did not meet one of its main goals in a late-stage trial.
GSK Completes Acquisition of Nuvalent to Expand Oncology Pipeline
GSK Completes Acquisition of Nuvalent to Expand Oncology Pipeline
GSK completes acquisition of Nuvalent
GSK (GSK) announced completion of its acquisition of Nuvalent. The acquisition adds three lung cancer assets to GSK’s oncology portfolio. Zidesamtinib and neladalkib are considered potential best-in-c...
GSK Achieves Promising Results in Rectal Cancer Trial with Jemperli
GSK Achieves Promising Results in Rectal Cancer Trial with Jemperli
Nuvalent Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nuvalent, Inc. - NUVL
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
GSK: Positive Phase II Results for Jemperli in Advanced Rectal Cancer
GSK: Positive Phase II Results for Jemperli in Advanced Rectal Cancer
GSK reports Jemperli single arm trial met its primary objective
GSK (GSK) plc announced “positive” interim results from the registrational phase II AZUR-1 trial of Jemperli in patients with stage II/III mismatch repair deficient/microsatellite instability-high loc...
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after...
GSK: Hansoh Pharma's Ris-Rez Shows Survival Benefit In Lung Cancer Trial
(RTTNews) - Hansoh Pharmaceutical Group, the licensor of GSK's investigational therapy Ris-Rez, announced positive Phase III results from its ARTEMIS-008 study in China, marking a major milestone in s...
GSK Achieves Phase 3 Trial Success for Risvutatug Rezetecan in Lung Cancer
GSK Achieves Phase 3 Trial Success for Risvutatug Rezetecan in Lung Cancer
GSK Achieves Key Milestone with Ris-Rez in Lung Cancer Trial
GSK Achieves Key Milestone with Ris-Rez in Lung Cancer Trial
GSK's targeted cancer therapy shows positive results in late-stage study
British drugmaker GSK's experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Friday.
GSK says Hansoh Pharma announces positive phase 3 results for Ris-Rez in China
GSK (GSK) plc licensor Hansoh Pharmaceutical Group announced that ARTEMIS-008, its pivotal phase III trial evaluating risvutatug rezetecan, or Ris-Rez, in patients with advanced or relapsed small-cell...
GSK price target raised to 1,950 GBp from 1,900 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on GSK (GSK) to 1,950 GBp from 1,900 GBp and keeps a Hold rating on the shares.